Blue Ridge Capital’s Medicines Co MDCO Stock Holding History

Blue Ridge Capital’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,100,000	Closed	-$53.8M	–	48
2017 Q1	$53.8M	Buy	+1,100,000	New	+$50.2M	0.7%	36

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Blue Ridge Capital's MDCO Position: Q2 2017 in Review

Blue Ridge Capital sold out of Medicines Co (MDCO) in Q2 2017, closing a stake of 1,100,000 shares — an estimated $53.8M sold.

Blue Ridge Capital first reported a position in MDCO in Q1 2017 and held it in 1 quarter. The position peaked at $53.8M in Q1 2017. 202 funds tracked by Wall St. Rank hold MDCO as of Q2 2017.

Blue Ridge Capital reported no remaining Medicines Co position as of Q2 2017 after selling out during the quarter.
Blue Ridge Capital sold 1,100,000 Medicines Co shares in Q2 2017, an estimated $53.8M.
Blue Ridge Capital first reported a position in Medicines Co in Q1 2017 and held it in 1 quarter.
Blue Ridge Capital's Medicines Co position peaked at $53.8M in Q1 2017.
202 funds tracked by Wall St. Rank held Medicines Co as of Q2 2017.

Based on Blue Ridge Capital's 13F filing for Q2 2017, filed 14 Aug 2017.